Further, naïve tumor-specific CD4+ T cells can naturally differentiate into Th1 cytotoxic T cells in vivo and cause the regression of established tumors in hosts with lymphopenia (11), supporting the potential for the use of tumor-reactive CD4+ T cells in cancer immunotherapy. Here, CD4 is linked to neoplasm.